Skip to main content

Clinical trial PIVeR

A multicentre, phase II, open label, single arm study of pixantrone in patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma treated with rituximab, ifosfamide and etoposide (PIVeR)

Cancers
Organ Multiple
Trial status Trial open for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 2
Academic trial Non
Sponsor LYSA LYmphoma
EudraCT Identifier 2017-000719-17
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03458260
Inclusion criteria -DLBCL CD20 +de novo or transformed from low grade NHL or follicular lymphoma grade 3b -relapsed or refractory : Patients eligible for ASCT who failed to achieve a CR after at least one salvage therapy Or patients in first relapse after ASCTOr patients
Last update